References
- Attard G, Reid AHM, Yap TA, et al (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol, 26, 4563-71. https://doi.org/10.1200/JCO.2007.15.9749
- Attard G, Reid AH, A'Hern R, et al (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol, 27, 3742-8. https://doi.org/10.1200/JCO.2008.20.0642
- Balshem H, Helfand M, Schunemann HJ, et al (2011). GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol, 64, 401-6. https://doi.org/10.1016/j.jclinepi.2010.07.015
- Beltran H, Beer TM, Carducci MA, et al (2011). New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol, 60, 279-90. https://doi.org/10.1016/j.eururo.2011.04.038
- Cersosimo RJ (2012). New agents for the management of castration-resistant prostate cancer. Ann Pharmacother, 46, 1518-28. https://doi.org/10.1345/aph.1R169
- Crawford ED, Eisenberger MA, McLeod DG, et al (1989). A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med, 321, 419-24. https://doi.org/10.1056/NEJM198908173210702
- Danila DC, Morris MJ, de Bono JS, et al (2010). Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol, 28, 1496-501. https://doi.org/10.1200/JCO.2009.25.9259
- de Bono JS, Logothetis CJ, Molina A, et al (2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 364, 1995-2005. https://doi.org/10.1056/NEJMoa1014618
- Di Lorenzo G, Ferro M, Buonerba C (2012). Sipuleucel-T (Provenge (R)) for castration-resistant prostate cancer. BJU Int, 110, E99-104. https://doi.org/10.1111/j.1464-410X.2011.10790.x
- Ding H, Yang L, Du W, et al (2013). Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 14, 3337-43. https://doi.org/10.7314/APJCP.2013.14.5.3337
- Fizazi K, Scher HI, Molina A, et al (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 13, 983-92. https://doi.org/10.1016/S1470-2045(12)70379-0
- Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A (2011). GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol, 64, 380-2. https://doi.org/10.1016/j.jclinepi.2010.09.011
- Higgins JPT, Green S (2011). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
- Kang DI, Chung JI, Ha HK, et al (2013). Korean prostate cancer patients have worse disease characteristics than their American counterparts. Asian Pac J Cancer Prev, 14, 6913-7. https://doi.org/10.7314/APJCP.2013.14.11.6913
- Logothetis CJ, Basch E, Molina A, et al (2012). Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol, 13, 1210-7. https://doi.org/10.1016/S1470-2045(12)70473-4
- Moore MA, Ariyaratne Y, Badar F, et al (2010). Cancer epidemiology in South Asia - past, present and future. Asian Pac J Cancer Prev, 11 Suppl 2, 49-66.
- Nandha R (2012). Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma. J Postgrad Med, 58, 203-6. https://doi.org/10.4103/0022-3859.101400
- Ostale S, Ruiz P (2012). Cost-efficacy analysis of licensed drugs for the treatment of metastatic castrate resistant prostate cancer post docetaxel based on hospital drug evaluation methodology in Spain. Value Health, 15, A417.
- Persson U, Nilsson S, Hjortsberg C, Prutz C (2012). Economic evaluation of abiraterone acetate as treatment for metastatic castration resistant prostate cancer after failure of docetaxel in Sweden. Value Health, 15, A219.
- Petrylak DP, Tangen CM, Hussain MH, et al (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351, 1513-20. https://doi.org/10.1056/NEJMoa041318
- Reid AHM, Attard G, Danila DC, et al (2010). Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol, 28, 1489-95. https://doi.org/10.1200/JCO.2009.24.6819
- Ryan CJ, Smith MR, Fong L, et al (2010). Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol, 28, 1481-8. https://doi.org/10.1200/JCO.2009.24.1281
- Ryan CJ, Shah S, Efstathiou E, et al (2011). Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res, 17, 4854-61. https://doi.org/10.1158/1078-0432.CCR-11-0815
- Ryan CJ, Smith MR, de Bono JS, et al (2012). Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med, 368, 138-48.
- Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
- Yang LPH (2011). Abiraterone acetate: In metastatic castrationresistant prostate cancer. Drugs, 71, 2067-77. https://doi.org/10.2165/11208080-000000000-00000
- Zhou ZR, Zhu XD, Xia J, et al (2013). Short-term versus longterm hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol, 139, 783-96. https://doi.org/10.1007/s00432-013-1383-7
Cited by
- A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer vol.10, pp.7, 2015, https://doi.org/10.1371/journal.pone.0133803
- Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer? vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.6167
- Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study vol.23, pp.5, 2016, https://doi.org/10.1111/iju.13051
- Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival vol.7, pp.1663-9812, 2016, https://doi.org/10.3389/fphar.2016.00123
- CYP17 inhibitors in prostate cancer: latest evidence and clinical potential vol.8, pp.4, 2016, https://doi.org/10.1177/1758834016642370
- Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel vol.28, pp.9, 2017, https://doi.org/10.1097/CAD.0000000000000549
- New horizons in the management of castrate-resistant prostate cancer pp.2051-4166, 2017, https://doi.org/10.1177/2051415817731397